Key result
Alteplase linked to ~82% lower in-hospital mortality in high-intermediate risk pulmonary embolism.
Why the study?
Thrombolytic treatment is a subject of debate in intermediate-risk acute pulmonary embolism (APE), motivating an investigation of its effects in patients subclassified into low-intermediate and high-intermediate risk groups.
Does thrombolytic therapy with alteplase reduce in-hospital APE-related mortality in patients with low-intermediate and high-intermediate risk acute pulmonary embolism?
Observational (n=227)
No
Does thrombolytic therapy with alteplase reduce in-hospital APE-related mortality in patients with low-intermediate and high-intermediate risk acute pulmonary embolism?
Sub-classifying intermediate-risk acute pulmonary embolism into low-intermediate and high-intermediate risk groups identifies high-intermediate risk patients who may derive an in-hospital survival benefit from systemic thrombolytic therapy with alteplase.
Answers are grounded in this paper and cite their sources.
Alteplase was associated with lower mortality in high-intermediate risk APE; leaves open confirmation by randomized trials before practice change.
Objective: The thrombolytic treatment is a subject of debate in acute pulmonary embolism (APE) with an intermediate risk for adverse outcomes. Our aim is to investigate retrospectively the effects of thrombolytics on mortality and other cardiovascular outcomes in intermediate-risk APE patients with further classification into low-intermediate or high-intermediate risk groups. Methods: The study included 227 patients diagnosed as APE. Mortality risk stratification was done according to the 2014 European Society of Cardiology guidelines on APE. The primary outcome was in-hospital death related to APE. A composite of hemodynamic deterioration, cardiogenic shock, and total mortality was defined as the composite clinical endpoint. Results: One hundred and sixty-nine (74.4%) of patients were classified as low-intermediate risk, and 58 (25.6%) of patients were classified as high-intermediate risk. The total number of patients who received alteplase (tissue plasminogen activator) was 157 (69.2%), with no difference between both groups (p=0.97). In the low-intermediate risk group, there were no differences in primary and composite endpoints regarding to thrombolytic therapy. In the high-intermediate risk group, both total mortality and APE-related mortality were lower in patients treated with thrombolytics (p=0.025 for both). Conclusion: Classifying patients into low-intermediate and high-intermediate risk subsets is helpful for determining patients who may benefit from thrombolytic treatment.
No takes yet. Share an insight, caveat, or question.
Börklü et al. (2026) conducted an observational in Intermediate-risk acute pulmonary embolism (n=227). Alteplase (tPA) plus unfractionated heparin vs. Anticoagulation alone (unfractionated heparin or enoxaparin) was evaluated on In-hospital mortality in the high-intermediate risk subgroup (HR 0.182, 95% CI 0.05-0.73, p=0.045). Alteplase thrombolytic therapy improved in-hospital survival in high-intermediate risk acute pulmonary embolism patients, but not in low-intermediate risk patients.
Synapse has enriched 10 related papers. Consider them for comparative context: